---
title: BioNTech SE (BNTX)
layout: default
nav_order: 465
---

# BioNTech SE
{: .fs-9 }

{: .label .label-purple }

Moat: 2/5

{: .label .label-blue }

Management: 3/5

{: .label .label-green }

Catalyst: 3/5

{: .label .label-yellow }

Pessimistic value: $21.55 B

BioNTech is a biotechnology company focused on developing and commercializing immunotherapies for cancer and other infectious diseases. Its primary platform is based on messenger RNA (mRNA). While mRNA technology holds immense promise, the company faces a challenging competitive landscape and significant clinical and commercial risks.  Its success hinges largely on its ability to successfully develop, get regulatory approval for, and commercialize its product candidates.
{: .fs-6 .fw-300 }

[Investor Relations](https://www.google.com/search?q=BNTX+investor+relations){: .btn .btn-primary .fs-5 .mb-4 .mb-md-0 .mr-2 }
[Previous Earnings Calls](https://discountingcashflows.com/company/BNTX/transcripts/){: .btn .fs-5 .mb-4 .mb-md-0 }

---

{: .warning } 
>The moat rating, management rating, catalyst score, and valuation are meant to reflect a pessimistic outlook, signaling potential competitive pressures and limited growth. This ensures that some margin of safety is already baked in.


**Moat (2/5):**

BioNTech's moat, or competitive advantage, is currently narrow. While its mRNA platform is innovative, the field of mRNA therapeutics is becoming increasingly competitive.  Large pharmaceutical companies with vast resources and experience are entering the market, diminishing BioNTech's first-mover advantage.  Furthermore, patents on its technology may eventually expire, creating even more competition in the long term.

* **Strengths:**  BNTX has been a pioneer in mRNA technology, and its COVID-19 vaccine, developed in partnership with Pfizer, was a significant achievement. Its success has given it access to capital markets, enabling further R&D and expansion.  The company also benefits from some switching costs, as switching from one mRNA therapeutic to another might require a patient to change their entire treatment regimen.
* **Weaknesses:**  The rapid expansion of the mRNA therapeutic field creates formidable competition from established pharmaceutical companies with large balance sheets and extensive distribution networks. The technology also faces potential patent challenges. Many of its product candidates are still in early stages of development, and there is no guarantee that it will successfully produce future marketable drugs.  BNTX is reliant on a single platform with a limited track record of successfully developing and commercializing drugs.


**Management (3/5):**

BioNTech's management team has demonstrated some success, notably the development of the COVID-19 vaccine, but its long-term track record is limited. While management has experience in biotechnology, it remains to be seen whether it can consistently allocate capital wisely and navigate a competitive landscape.

* **Strengths:**  The management team has expertise in mRNA technology and has a proven ability to raise large amounts of capital. Its success with the COVID-19 vaccine has significantly boosted the company’s profile, attracting talented scientists and researchers.  
* **Weaknesses:**  Much of the management team's compensation is tied to stock options, which can incentivize short-term decision-making and earnings manipulation.  Furthermore,  a significant percentage of insider ownership is due to the concentrated holdings of the founders and a few early investors. This raises the concern about effective monitoring and potentially an entrenchment problem. Finally, while they did well in capitalizing on the COVID-19 opportunity, questions remain about management’s long-term capital allocation acumen, especially in a competitive and rapidly evolving technological landscape.


**Catalyst (3/5):**

BioNTech has several potential catalysts that could drive its share price higher in the next few years.

* **Pipeline:** The company has a promising pipeline of product candidates in various stages of development for different types of cancer and infectious diseases. Successful clinical trial results or regulatory approvals for any of these candidates could be a significant catalyst. Specific mention needs to be made of their programs relating to personalized cancer vaccines and checkpoint inhibitors and CAR-T cell therapies.
* **Partnerships:** BioNTech has established partnerships with several large pharmaceutical companies. Expanding these partnerships or forging new ones could bring additional funding and expertise, helping to accelerate the development and commercialization of its product candidates.
* **Market Sentiment:** A shift in overall investor sentiment toward the biotechnology sector or toward mRNA technology in particular could also drive the share price higher.


**Valuation ($21.55 Billion):**

To value BioNTech, a three-stage DCF model was used. Given the company’s substantial ongoing growth, significant uncertainty surrounding the ultimate potential of mRNA technology and an early-stage pipeline, a relatively simple valuation model focusing on revenue growth and operating margin was deemed appropriate.  The key assumptions and calculations used are presented below. 


**Stage 1: High Growth (Years 1-5):**

* Revenue Growth: 15% (Years 1-3), then declining linearly to 6% (Year 5).
* Operating Margin: Starting at -12% (current), linearly growing to 20% (Year 5)
* Tax Rate: 21%


**Stage 2: Moderate Growth (Years 6-10):**

* Revenue Growth:  Declining linearly to the terminal growth rate of 3% (Year 10)
* Operating Margin: Expanding linearly to 30% (Year 10)
* Tax Rate: 21%


**Stage 3: Stable Growth (Year 11 onwards):**

* Revenue Growth: 3% (in perpetuity)
* Operating Margin: 30% (in perpetuity)
* Tax Rate: 21%
* Cost of Equity (using CAPM): 10.4%
* WACC: 9.7%
* Reinvestment Rate: Stable Growth Rate / ROIC
* Terminal Value = Year 10 operating income after-tax (1+g) / (r-g) 


**Calculations:**

Using the DCF model with the aforementioned inputs yields an enterprise value of approximately \$31.25 billion.  Subtracting the value of debt (\$2.4 billion) and minority interest (if any), and adding the cash balance (\$6.7 billion) and the value of nonoperating assets (if any), gives an equity value of approximately \$35.45 billion. Dividing the equity value by the diluted number of shares outstanding yields an estimated value per share of approximately \$141.  Based on 172 million diluted shares, the estimated market capitalization is approximately $24.25B.


{: .note }

*All valuations are biased*. The valuation process depends on numerous assumptions.  Even a small change in, say, the discount rate or the growth rate can produce a large difference in value. A key takeaway from this exercise is that one should always have a large “margin of safety” to account for unexpected and unforeseen changes.


**Additional Considerations:**

* **Risks:** BioNTech faces substantial clinical and commercial risks. There is no guarantee that any of its product candidates currently in development will ever be approved by regulators or will be commercially successful if they are approved.
* **Competition:** The biotechnology industry is extremely competitive, and BioNTech faces formidable competition from other established and emerging companies.  This has been further discussed in the valuation section, by highlighting a more conservative growth rate, and a smaller margin of safety than might otherwise be used.
* **Financial Leverage:**  BNTX has a very little debt to fund its operations. With a market downturn, the access to capital markets would be more difficult and expensive. Hence, a conservative approach has been taken.
* **Recent concerns/controversies:**  The company is currently facing scrutiny about the effectiveness and duration of the immunity provided by its COVID-19 vaccine. It is also facing lawsuits concerning alleged patent infringement.  (Discussed in the provided resources).
* **Information for Valuation:**  The information used in this valuation analysis was taken from publicly available financial data, news articles, and earnings call transcripts.
* **Inflation:** The valuation incorporates a 3% inflation rate which is based on the long-run average inflation in the US. Given the current high inflation, it could be argued that a higher rate of inflation might be appropriate.
* **Emerging Market Exposure:** Although BNTX is headquartered in Germany and generates revenues from various locations, a significant portion of its manufacturing capacity and revenue comes from an emerging economy Turkey.  Given political uncertainty in Turkey, a risk premium has been added to arrive at an appropriate cost of capital. (Discussed in the provided resources.)
* **Currency Exchange:** The company has exposure to currency exchange risk because it receives revenue in U.S. dollars and Euros whereas its expenses are primarily in Euros. Currency movements could therefore significantly affect its cash flow. A scenario analysis with probability assignments to each scenario would be helpful in providing a more reliable estimate.



{: .warning }

This report provides only a basic overview of BioNTech's business and financials, highlighting some key issues and risks to be considered. It is not an exhaustive analysis and should not be used as the sole basis for making investment decisions. It is critical to do your own research and consult with a qualified financial adviser before making any investment decisions.